Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Conducting $845 Million IPO in Hong Kong

publication date: Sep 17, 2020

Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise $845 million, based on the price of the company's US-listed shares. On the NASDAQ Exchange, Zai has a market capitalization of $6.2 billion. The company is developing a large portfolio of in-licensed cancer and infectious disease candidates. Its PARP inhibitor is approved for China use in ovarian cancer and a medical device, Tumor Treating Fields, is approved in China for glioblastoma. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital